

Agnes I Vitry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7703717/publications.pdf>

Version: 2024-02-01

95
papers

3,004
citations

186265

28
h-index

175258

52
g-index

96
all docs

96
docs citations

96
times ranked

4107
citing authors

#	ARTICLE	IF	CITATIONS
1	“Food for Thought” – The Relationship between Diet and Cognition in Breast and Colorectal Cancer Survivors: A Feasibility Study. <i>Nutrients</i> , 2022, 14, 71.	4.1	3
2	Access to Controlled Medicines in Low-Income Countries: Listening to Stakeholders in the Field. <i>International Journal of Health Services</i> , 2021, 51, 404-411.	2.5	3
3	“Drugs to avoid” to improve quality use of medicines: how is Australia faring?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 60.	2.4	3
4	Evaluating changes in student health, wellbeing and social circumstances before and during COVID-19 pandemic restrictions in Australia. <i>PeerJ</i> , 2021, 9, e12078.	2.0	3
5	“Drugs to avoid”: can we improve prescribing appropriateness?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 162-162.	0.3	0
6	Patterns of health service utilisation among the Australian population with cancer compared with the general population. <i>Australian Health Review</i> , 2020, 44, 470.	1.1	8
7	OUP accepted manuscript. <i>International Journal for Quality in Health Care</i> , 2019, 31, 647-653.	1.8	2
8	Patterns of comorbidities in women with breast cancer: a Canadian population-based study. <i>Cancer Causes and Control</i> , 2019, 30, 931-941.	1.8	40
9	Flawed evidence underpins approval of new cancer drugs. <i>BMJ: British Medical Journal</i> , 2019, 366, l5399.	2.3	7
10	Medication-related quality of care in residential aged care: an Australian experience. <i>International Journal for Quality in Health Care</i> , 2019, 31, 298-306.	1.8	9
11	Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis. <i>International Journal of Health Services</i> , 2019, 49, 273-293.	2.5	21
12	Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study. <i>Health Policy</i> , 2018, 122, 243-249.	3.0	5
13	Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 403-410.	3.9	39
14	Changes in the prevalence of comorbidity in the Australian population with cancer, 2007–2014. <i>Cancer Epidemiology</i> , 2018, 54, 56-62.	1.9	11
15	Comorbidity, physical and mental health among cancer patients and survivors: An Australian population-based study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e181-e192.	1.1	56
16	Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study. <i>Journal of Comorbidity</i> , 2018, 8, 16-24.	3.9	12
17	Comorbidities in Australian women with hormone-dependent breast cancer: a population-based analysis. <i>Medical Journal of Australia</i> , 2018, 208, 24-28.	1.7	17
18	Disease burden, comorbidity and geriatric syndromes in the Australian aged care population. <i>Australasian Journal on Ageing</i> , 2017, 36, E14-E19.	0.9	28

#	ARTICLE	IF	CITATIONS
19	Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis. <i>Asia-Pacific Journal of Public Health</i> , 2017, 29, 268-277.	1.0	19
20	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1795-1797.	1.9	1
21	Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 131-140.	1.8	16
22	Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. <i>Medical Journal of Australia</i> , 2016, 204, 64-68.	1.7	14
23	Analgesic use and pain in residents with and without dementia in aged care facilities: A cross-sectional study. <i>Australasian Journal on Ageing</i> , 2016, 35, 180-187.	0.9	31
24	Pricing and utilisation of proton pump inhibitors in South Australian public hospitals and the Pharmaceutical Benefits Scheme. <i>Journal of Pharmacy Practice and Research</i> , 2016, 46, 130-136.	0.8	3
25	Trends in general practitioner services to residents in aged care. <i>Australian Journal of Primary Health</i> , 2016, 22, 517.	0.9	10
26	Access to new cancer medicines in Australia: dispelling the myths and informing a public debate. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 13.	2.4	17
27	Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. <i>Lancet Oncology</i> , The, 2016, 17, 39-47.	10.7	137
28	Editorial: Transparency is good, independence from pharmaceutical industry is better. <i>Australian Prescriber</i> , 2016, 39, 112-113.	1.0	3
29	Approval, reimbursement and pricing of high-cost cancer medicines in Australia. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	2.4	2
30	Prices of oncology medicines in European countries, Australia and New Zealand. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	2.4	1
31	Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	2.4	2
32	Doctors' views on the quality of claims provided by pharmaceutical representatives: A comparative study in Malaysia and Australia. <i>Journal of Taibah University Medical Sciences</i> , 2015, 10, 471-480.	0.9	3
33	Evaluating medication-related quality of care in residential aged care: a systematic review. SpringerPlus, 2015, 4, 220.	1.2	21
34	Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, 25.	2.4	33
35	Analgesic Use and Daytime Sleepiness in Residents With and Without Dementia in Residential Aged Care Facilities. <i>Drugs and Aging</i> , 2015, 32, 1045-1053.	2.7	11
36	Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 76-82.	1.5	19

#	ARTICLE	IF	CITATIONS
37	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. <i>GaBI Journal</i> , 2015, 4, 125-135.	0.3	10
38	Analgesic use, pain and daytime sedation in people with and without dementia in aged care facilities: a cross-sectional, multisite, epidemiological study protocol. <i>BMJ Open</i> , 2014, 4, e005757-e005757.	1.9	34
39	General practitioner management plans delaying time to next potentially preventable hospitalisation for patients with heart failure. <i>Internal Medicine Journal</i> , 2014, 44, 1117-1123.	0.8	19
40	Managed entry agreements for pharmaceuticals in Australia. <i>Health Policy</i> , 2014, 117, 345-352.	3.0	48
41	Discounting of medicines in Australian community pharmacies. <i>Australian Health Review</i> , 2014, 38, 517.	1.1	2
42	Assessment of the therapeutic value of new medicines marketed in Australia. <i>Journal of Pharmaceutical Policy and Practice</i> , 2013, 6, 2.	2.4	14
43	Does antidepressant medication use affect persistence with diabetes medicines?. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 615-622.	1.9	18
44	Comorbid Diabetes and COPD. <i>Diabetes Care</i> , 2013, 36, 3009-3014.	8.6	48
45	Serious statin-associated myotoxicity and rhabdomyolysis in atorvastatin and simvastatin: a case series. <i>Internal Medicine Journal</i> , 2013, 43, 987-992.	0.8	17
46	Response to Michael Wonderlin's comments on the article "Assessment of the therapeutic value of new medicines marketed in Australia". <i>Journal of Pharmaceutical Policy and Practice</i> , 2013, 6, 8.	2.4	6
47	Chronic disease management: does the disease affect likelihood of care planning?. <i>Australian Health Review</i> , 2012, 36, 419.	1.1	9
48	Disease mongering and low testosterone in men: the tale of two regulatory failures. <i>Medical Journal of Australia</i> , 2012, 196, 619-621.	1.7	16
49	What lessons can be learned from the launch of generic clopidogrel?. <i>GaBI Journal</i> , 2012, 1, 58-68.	0.3	24
50	Co-Morbidity and Potential Treatment Conflicts in Elderly Heart Failure Patients. <i>Drugs and Aging</i> , 2011, 28, 575-581.	2.7	36
51	The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 115-120.	2.8	5
52	Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 223-228.	5.0	74
53	Multimorbidity, care complexity and prescribing for the elderly. <i>Aging Health</i> , 2011, 7, 695-705.	0.3	39
54	Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. <i>Internal Medicine Journal</i> , 2011, 41, 162-166.	0.8	10

#	ARTICLE	IF	CITATIONS
55	Ageing well: Improving the management of patients with multiple chronic health problems. <i>Australasian Journal on Ageing</i> , 2011, 30, 32-37.	0.9	22
56	Major bleeding risk associated with warfarin and coâ€medications in the elderly population. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1057-1063.	1.9	47
57	Antidepressant use and depressive symptomatology among older people from the Australian Longitudinal Study of Ageing. <i>International Psychogeriatrics</i> , 2010, 22, 437-444.	1.0	25
58	Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. <i>International Journal of Pharmacy Practice</i> , 2010, 13, 53-70.	0.6	84
59	Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. <i>BMC Public Health</i> , 2010, 10, 294.	2.9	18
60	Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. <i>BMC Public Health</i> , 2010, 10, 743.	2.9	25
61	The risk of falls and fractures associated with persistent use of psychotropic medications in elderly people. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, e1-e4.	3.0	20
62	Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing?. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 977-982.	1.9	48
63	Prasugrel vs. clopidogrel for cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1678-1684.	3.8	92
64	Reporting of Studies on New Medicines in Major Medical Journals: A Case Study in Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 398-400.	4.7	5
65	Coâ€morbidity and the utilization of health care for Australian veterans with diabetes. <i>Diabetic Medicine</i> , 2010, 27, 65-71.	2.3	15
66	Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study. <i>PLoS ONE</i> , 2010, 5, e14024.	2.5	36
67	Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 1036-1042.	3.7	98
68	Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 71-76.	2.8	15
69	Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. <i>Age and Ageing</i> , 2010, 39, 488-494.	1.6	44
70	Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000352.	8.4	385
71	Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. <i>Diabetes Research and Clinical Practice</i> , 2010, 87, 385-393.	2.8	153
72	Self-medication with over-the-counter drugs and complementary medications in South Australia's elderly population. <i>BMC Complementary and Alternative Medicine</i> , 2009, 9, 42.	3.7	96

#	ARTICLE	IF	CITATIONS
73	Provision of medicines information in Australian community pharmacies. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 154-157.	1.4	5
74	Drug-related problems identified in medication reviews by Australian pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 216-223.	1.4	63
75	Written medicine information in Australia, answer to the letter to the editor. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 605-606.	1.4	0
76	Advertising of antihypertensive medicines and prescription sales in Australia. <i>Internal Medicine Journal</i> , 2009, 39, 728-732.	0.8	6
77	Validity of medication-based comorbidity indices in the Australian elderly population. <i>Australian and New Zealand Journal of Public Health</i> , 2009, 33, 126-130.	1.8	90
78	Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. <i>PLoS ONE</i> , 2009, 4, e6350.	2.5	76
79	Does Direct-to-Consumer Prescription Drug Advertising Do More Harm Than Good?. <i>Annals of Internal Medicine</i> , 2009, 151, 823.	3.9	1
80	Provision of information on regulatory authorities'™ websites. <i>Internal Medicine Journal</i> , 2008, 38, 559-567.	0.8	16
81	Prevalence of comorbidity of chronic diseases in Australia. <i>BMC Public Health</i> , 2008, 8, 221.	2.9	189
82	Quality and availability of consumer information on heart failure in Australia. <i>BMC Health Services Research</i> , 2008, 8, 255.	2.2	6
83	The Australian funding debate on quadrivalent HPV vaccine: A case study for the national pharmaceutical policy. <i>Health Policy</i> , 2008, 88, 250-257.	3.0	26
84	Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. <i>Medical Journal of Australia</i> , 2008, 189, 360-365.	1.7	86
85	Time for transparency at the TGA. <i>Australian Prescriber</i> , 2008, 31, 114-115.	1.0	1
86	Is Australia's National Medicines Policy Failing? the Case of Cox-2 Inhibitors. <i>International Journal of Health Services</i> , 2007, 37, 735-744.	2.5	1
87	Direct-to-consumer advertising policy in Australia: realism in whose interests?. <i>Internal Medicine Journal</i> , 2007, 37, 665-666.	0.8	2
88	Comparative assessment of four drug interaction compendia. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 709-714.	2.4	133
89	Pharmaceutical advertisements in prescribing software: an analysis. <i>Medical Journal of Australia</i> , 2005, 183, 75-79.	1.7	12
90	Drug advertising in medical journals. <i>Lancet, The</i> , 2003, 361, 879.	13.7	3

#	ARTICLE	IF	CITATIONS
91	The road to consensus: considerations for the safe use and prescribing of COX-2 specific inhibitors. Medical Journal of Australia, 2002, 177, 572-573.	1.7	2
92	Drug advertisements in medical journals. Lancet, The, 1997, 350, 1477-1478.	13.7	3
93	Promotion of Coversyl by Servier. Lancet, The, 1996, 347, 1411.	13.7	3
94	Drug marketing in french-speaking African countries. Social Science and Medicine, 1993, 36, 1541-1543.	3.8	10
95	France: Stricter rules for drug exports. Lancet, The, 1992, 340, 167.	13.7	0